---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-24-000025"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:25:58.220262+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M

## Summary
- Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.
- Full-year 2023 revenue $159.0M (+14.7% YoY); net loss $21.7M vs $28.9M in 2022.
- Gross margin declined: Q4 78.7% vs 83.0%; FY 80.4% vs 82.6%. Guidance expects 76-79% for 2024.
- FDA pre-BLA agreement for Avance nerve graft; rolling submission in Q3 2024, potential approval mid-2025.
- Avive+ Soft Tissue Matrix launch planned in Q2 2024; core accounts grew 13.3% to 376.

## SEC filing metadata
- accession: 0000805928-24-000025
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/0000805928-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/axgn-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-24-000025
- JSON: https://secwatch.observer/filing/0000805928-24-000025.json
- Plain text: https://secwatch.observer/filing/0000805928-24-000025.txt

## Key facts
- Earnings Releases
  Axogen, Inc. updated its the fourth quarter and full-year ended December 31, 2023 guidance (raised).
  - Period: the fourth quarter and full-year ended December 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On March 5, 2024 Axogen, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/0000805928-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.